(CERT) Certara - Ratings and Ratios

Certara, Inc. (NASDAQ:CERT) is a leader in technology-enabled services and software products for biosimulation across the drug development lifecycle. The company supports model-informed drug development through advanced biosimulation solutions, enabling precise predictions of pharmacokinetics and pharmacodynamics. Its offerings include the Simcyp simulator, a physiologically based pharmacokinetic platform, and specialized tools like Simcyp Discovery for pre-investigational new drug stages, Simcyp Biopharmaceutics for formulation optimization, and Simcyp Secondary Intelligence for integrating toxicology with biological network analysis.

The companys portfolio extends to Phoenix WinNonlin for non-compartmental analysis, Phoenix Hosted for secure cloud-based workspaces, and Phoenix NLME for population modeling. Additionally, Certara provides Pirana Modeling Workbench for iterative modeling processes, Chemaxon JChem engines for chemical searches, Chemaxon Compound Registration for lead optimization, Chemaxon Design Hub for drug discovery collaboration, and Certara D360 for scientific informatics in small molecule and biologics research.

Certara also offers Pinnacle 21 for clinical data automation, Pinnacle 21 Data Exchange for data standardization, Metadata Repository for controlled study design, CoAuthor for regulatory submissions, and GlobalSubmit for submissions management. These tools collectively streamline processes from discovery to regulatory submissions, enhancing efficiency and accuracy in drug development.

Ticker Symbol: CERT Exchange: NASDAQ Type: common stock Country Origin: United States GICS Sub Industry: Health Care Technology

Average Volume 20d: 2,160,982 Last Price: 13.89 SMA 20: 12.32 SMA 50: 11.83 SMA 200: 12.01 ATR: 0.78

Market Cap: $2,328.49M USD P/E: None P/E Forward: 31.35 P/B: 2.16 P/S: 6.05 RoE: -1.14

3-Month Forecast: Based on the technical and fundamental data, Certaras stock is expected to show moderate volatility with a potential upside driven by its position in the growing biosimulation market. The SMA 20 and SMA 50 indicate recent price strength, while the ATR suggests manageable volatility. Fundamental metrics like P/S and P/B are within industry norms, supporting stability. The forward P/E of 31.35 reflects market confidence in future earnings growth.